DAVID A contact WOHL
Affiliation: University of North Carolina
- The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefitDavid A Wohl
University of North Carolina, Chapel Hill, North Carolina, United States of America
PLoS ONE 8:e78676. 2013..The clinical outcomes of continued ART prescription for such patients have not been well characterized...
- Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)David A Wohl
The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Antivir Ther 19:191-200. 2014....
- Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) studyDavid A Wohl
Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA
Antivir Ther 19:141-7. 2014..Putative mechanisms for an effect of ABC on CVD risk including endothelial dysfunction have been proposed; however, a biological mechanism has not been established...
- Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) studyDavid A Wohl
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Antimicrob Agents Chemother 57:784-8. 2013..Based on plasma PK, and with similar adherence rates, the performance of RAL among HIV-infected African-Americans should be no different than that of infected patients who are white...
- Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapyDavid A Wohl
University of North Carolina, Chapel Hill, NC 27599, USA
Clin Infect Dis 47:1105-8. 2008..5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P = .04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin...
- Management of morphologic changes associated with antiretroviral use in HIV-infected patientsDavid Alain Wohl
AIDS Clinical Trials Unit, University of North Carolina, Chapel Hill, NC 27599, USA
J Acquir Immune Defic Syndr 49:S93-S100. 2008..The potential increase in risk of cardiovascular disease associated with these metabolic disturbances is also discussed...
- Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030D A Wohl
University of North Carolina, Chapel Hill, North Carolina, USA
HIV Clin Trials 10:143-52. 2009....
- Considering metabolic issues when initiating HIV therapyDavid Alain Wohl
The University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
Curr HIV/AIDS Rep 4:119-25. 2007....
- Deconstructing most recent antiretroviral recommendationsDavid Alain Wohl
AIDS Clinical Trials Unit Chapel Hill, Division of Infectious Diseases, The University of North Carolina at Chapel Hill, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
Curr HIV/AIDS Rep 7:77-84. 2010..Understanding the recommendations of the major US treatment guideline for initial HIV therapy is essential for clinicians caring for such patients...
- Locating the places people meet new sexual partners in a southern US city to inform HIV/STI prevention and testing effortsDavid A Wohl
The Center for AIDS Research, The University of North Carolina at Chapel Hill, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
AIDS Behav 15:283-91. 2011..The systematic methodology used was successful in locating venues where risky encounters are established and reveal opportunities for targeted HIV prevention and testing programs as well as research...
- Intensive case management before and after prison release is no more effective than comprehensive pre-release discharge planning in linking HIV-infected prisoners to care: a randomized trialDavid A Wohl
The University of North Carolina at Chapel Hill, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
AIDS Behav 15:356-64. 2011....
- Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapyD A Wohl
Div of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
Clin Infect Dis 43:645-53. 2006..On the basis of a review of the medical literature published and/or data presented before April 2006, we have prepared a guide to assist the clinician in the detection and management of these complications...
- Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemiaDavid A Wohl
Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
Clin Infect Dis 41:1498-504. 2005..Whether omega-3 fatty acid supplementation can reduce hypertriglyceridemia associated with antiretroviral therapy is not known...
- Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapiesDavid A Wohl
Division of Infectious Diseases, The University of North Carolina, Chapel Hill, NC 27599, USA
J Acquir Immune Defic Syndr 38:538-44. 2005..To determine the association of cytomegalovirus (CMV) viremia with CMV disease and death in patients with AIDS...
- Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267David A Wohl
Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
J Infect Dis 185:1359-63. 2002..Previous suggestions of autoinduction of drug metabolism were not confirmed by this study. At the doses studied, thalidomide was tolerated well and had linear pharmacokinetics...
- Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmatesDavid A Wohl
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, 27599, USA
Clin Infect Dis 36:1572-6. 2003..Different methods used to measure adherence revealed significantly different levels of adherence. These findings suggest that use of DOT does not ensure adherence to antiretroviral therapy...
- The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapyD A Wohl
University of North Carolina, Chapel Hill, North Carolina 27516 7215, USA
HIV Clin Trials 6:136-46. 2005....
- Body shape, lipid, and cardiovascular complications of HIV therapyDavid Alain Wohl
AIDS Research and Treatment Unit, University of North Carolina, Chapel Hill, NC 27599, USA
Curr HIV/AIDS Rep 2:74-82. 2005..Development of antiretrovirals with fewer metabolic adverse effects will reduce the incidence of these and similar disorders during HIV therapy...
- Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicityDavid A Wohl
Department of Medicine, University of North Carolina, Chapel Hill, USA
J Acquir Immune Defic Syndr 35:274-8. 2004..This variability may reflect differences in the definition of and risk factors for hyperlactatemia and/or techniques for venous lactate collection...
- Characteristics and behaviors associated with HIV infection among inmates in the North Carolina prison systemDavid L Rosen
University of North Carolina, Chapel Hill, 27599 7435, USA
Am J Public Health 99:1123-30. 2009..We identified factors associated with testing HIV positive in a prison system performing voluntary HIV testing on inmates and estimated the number of undetected HIV cases to evaluate the efficacy of risk-factor-based HIV testing...
- All-cause and cause-specific mortality among men released from state prison, 1980-2005David L Rosen
University of North Carolina Schools of Medicine and Public Health, Chapel Hill, NC, USA
Am J Public Health 98:2278-84. 2008..We compared mortality of ex-prisoners and other state residents to identify unmet health care needs among former prisoners...
- Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758Charles B Hicks
Department of Medicine, Duke University, Durham, North Carolina 27710, USA
AIDS Res Hum Retroviruses 25:395-403. 2009..48 mg/dl). In conclusion, through 96 weeks, FPV/r100 was more effective and prompted less elevation in triglycerides than FPV/r200...
- Sexual behaviours of HIV-seropositive men and women following release from prisonBecky L Stephenson
Schools of Medicine, Public Health, Nursing, and Dentistry at the University of North Carolina, Chapel Hill, NC 27599, USA
Int J STD AIDS 17:103-8. 2006..These results suggest that regular partners of HIV-infected prison releasees are at risk of acquiring HIV infection, and secondary risk-reduction strategies are needed for HIV-infected prison releasees...
- An evaluation of HIV testing among inmates in the North Carolina prison systemDavid L Rosen
Schools of Public Health and Medicine, University of North Carolina, Chapel, Chapel Hill, NC, 27599 7435, USA
Am J Public Health 99:S452-9. 2009..We examined the use of voluntary HIV testing among state prisoners in the North Carolina prison system...
- Predictors of repeat testing and HIV seroconversion in a sexually transmitted disease clinic populationLisa B Hightow
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Sex Transm Dis 31:455-9. 2004..This study assessed the extent of and characteristics associated with repeat HIV testing in persons presenting to a sexually transmitted disease (STD) clinic...
- Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapiesDavid A Wohl
University of North Carolina, Chapell Hill, NC, USA
Top HIV Med 12:89-93. 2004..This article summarizes a presentation by David A. Wohl, MD, at the February 2004 International AIDS Society-USA course in Atlanta...
- Timing and duration of incarceration and high-risk sexual partnerships among African Americans in North CarolinaMaria R Khan
Department of Epidemiology, University of North Carolina at Chapel Hill, NC, USA
Ann Epidemiol 18:403-10. 2008..Incarceration may contribute to HIV transmission by disrupting stable partnerships and promoting high-risk partnerships. We investigated incarceration and high-risk partnerships among African Americans in North Carolina...
- Incarceration and risky sexual partnerships in a southern US cityMaria R Khan
Department of Epidemiology, School of Public Health, University of North Carolina, CB 7435, Chapel Hill, NC 27514, USA
J Urban Health 85:100-13. 2008..Correctional-facility and community-based HIV prevention, with substance abuse treatment, should reach currently and formerly incarcerated individuals and their sexual partners...
- Effect of release from prison and re-incarceration on the viral loads of HIV-infected individualsBecky L Stephenson
Division of Infectious Diseases, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
Public Health Rep 120:84-8. 2005..The purpose of this study was to determine the effect of release from prison and subsequent re-incarceration on the viral loads of HIV-infected individuals receiving highly active antiretroviral therapy (HAART)...
- Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophyC Scott Hultman
Division of Plastic and Reconstructive Surgery, University of North Carolina, Chapel Hill, North Carolina 27599 7195, USA
Ann Plast Surg 58:255-63. 2007..Medical treatment of fat redistribution is usually ineffective. We evaluated the efficacy and safety of the surgical management of HIV lipodystrophy...
- A pilot study of health beliefs and attitudes concerning measures of antiretroviral adherence among prisoners receiving directly observed antiretroviral therapyBecky L White
Department of Medicine, Center for Infectious Diseases, University of North Carolina Schools of Medicine and Public Health, Chapel Hill, North Carolina, USA
AIDS Patient Care STDS 20:408-17. 2006..72; p < 0.001). This study provides preliminary support for the psychometric properties of the survey in this correctional setting...
- Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patientsSonia Napravnik
Division of Infectious Diseases, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
AIDS 21:825-34. 2007..HIV-1 triple-class antiretroviral drug resistance (TC-DR) may substantially limit therapeutic options and compromise clinical outcomes...
- Availability of and access to medical services among HIV-infected inmates incarcerated in North Carolina county jailsDavid L Rosen
Department of Epidemiology, University of North Carolina at Chapel Hill, USA
J Health Care Poor Underserved 15:413-25. 2004..quot; Overall, our data indicate that few North Carolina jail inmates are tested for HIV. Greater protection of confidentiality may improve screening and treatment of HIV-infected inmates...
- HIV and incarceration: dual epidemicsDavid A Wohl
AIDS Clinical Research and Treatment Unit, University of North Carolina at Chapel Hill, USA
AIDS Read 16:247-50, 257-60. 2006..Interventions to enhance identification of infected inmates, prevention counseling, and treatment of inmates with HIV/AIDS are required to stem the contribution of incarceration to the spread of HIV infection...
- Editorial comment: fish oil to keep the cardiologist away?David Alain Wohl
AIDS Read 17:371. 2007
- HIV treatment series. Metabolic complications myths. Some misunderstandings about treatmentDavid Alain Wohl
Posit Aware 18:25-8. 2007
- Editorial comment: correcting facial lipoatrophy has little to do with vanityDavid Alain Wohl
AIDS Read 15:372. 2005
- Diagnosing primary HIV infectionChristopher D Pilcher
Ann Intern Med 136:488-9; author reply 488-9. 2002
- HIV+ Prison Releases to Access to HIV Care and ServicesDavid Wohl; Fiscal Year: 2007..2. BCM will reduce intimate and drug related HIV transmission risk behaviors during the year following prison release. ..
- Incarceration and HIV-Infected InmatesDavid A Wohl; Fiscal Year: 2010..Aim 2. Determine the inmate, nurse-counselor and facility characteristics associated with agreeing to HIV VCT. Aim 3. Explore the risks associated with receiving an HIV diagnosis in prison. ..